Dr. Christopher Peter Luscy, MD

Dr. Luscy practices at Renal Associates of Baton Rouge in Baton Rouge, Louisiana.

Dr. Luscy's NPI, 1255338521, was assigned on July 1, 2005. Dr. Luscy holds Louisiana license 022165.

Dr. Luscy's primary practice is Renal Associates of Baton Rouge, at 5131 O'donovan Dr, Baton Rouge, LA 70808 in East Baton Rouge Parish. The practice phone is (225) 767-4893.

Dr. Luscy's primary practice is Renal Associates of Baton Rouge in Baton Rouge, Louisiana. Dr. Luscy is also affiliated with Our Lady of the Lake Regional Medical Center. The medical group on file is Ochsner Health. Dmand AI also links Dr. Luscy to 2 more hospitals, 3 group practices and clinics, 2 medical groups and 1 dialysis center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Luscy practices, 7 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Luscy's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Luscy is licensed in Louisiana.

CMS data shows 1,218 Medicare services from Dr. Luscy across 21 procedure codes in 2024, for 445 Medicare patients. Medicare paid $141,897 for them.

CMS counts 445 Medicare patients who saw Dr. Luscy in 2024. The largest group is 65 to 74, with 167 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 30% are also on Medicaid. Their average risk score is 5.51, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Luscy's median patient age at 68, with 47% women.

In 2024, Dr. Luscy wrote 1,022 Medicare Part D claims for 172 patients. 76% of them were for generic drugs. CMS names the drug for 834 of them, across 31 drugs with 11 or more claims each, at $417,177 in total drug cost. In 2023, CMS named 931 claims across 27 drugs.

Dr. Luscy accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Luscy as offering telehealth.

Dmand AI links Dr. Luscy to 1 clinical trial. Conditions studied include Renal Insufficiency, Chronic and Renal Insufficiency.

CMS Open Payments shows 219 general payments to Dr. Luscy from 31 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 60% of the total. Novartis Pharmaceuticals Corporation paid the most, $2,899.